Pilot study: Evaluation of potential drug-drug interactions in hospitalized pediatric patients.

Autor:	Medina-Barajas F; Pharmacy Service, Nuevo Hospital Civil de Guadalajara 'Dr. Juan I. Menchaca', 750 Salvador Quevedo y Zubieta St., 44340, Guadalajara, Mexico. Electronic address: favyri.sp@gmail.com., Vázquez-Méndez E; Medical and Pharmaceutical Biotechnology Department, Centro de Asistencia en Tecnología y Diseño del Estado de Jalisco, 800 Normalistas Av., 44270, Guadalajara, Mexico. Electronic address: sttephie@hotmail.com., Pérez-Guerrero EE; Molecular Biology and Genomics Department, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., 44340, Guadalajara, Mexico. Electronic address: edsaul.perez@gmail.com., Sánchez-López VA; Pharmacovigilance Department, Laboratorios PiSA, 1840 España Ave., 44190, Guadalajara, Mexico. Electronic address: aleyda_sanmis7@hotmail.com., Hernández-Cañaveral II; Microbiology Department, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., 44340, Guadalajara, Mexico. Electronic address: ivanhzc21@yahoo.com.mx., Gabriel A RO; Centro integral de Medicina Ambiental y Toxicología CIMATOX S.A.S, de C.V. María Reyes 2, Guadalajara, Mexico. Electronic address: contacto@cimatox.com., Huerta-Olvera SG; Medical and Life Sciences Department, Centro Universitario de la Ciénega, Universidad de Guadalajara, 1115 Universidad Av., 47820, Ocotlán, Mexico. Electronic address: selene.huerta@academicos.udg.mx.
Jazyk:	angličtina
Zdroj:	Pediatrics and neonatology [Pediatr Neonatol] 2020 Jun; Vol. 61 (3), pp. 279-289. Date of Electronic Publication: 2019 Nov 22.
DOI:	10.1016/j.pedneo.2019.11.006
Abstrakt:	Purpose: Evaluate the type and severity of potential drug-drug interactions and identify risk factors involved, in pediatric patients admitted in a hospital setting. Methods: Transversal retrospective analytical study was carried out with hospitalized pediatric patients from a Hospital in the West of Mexico, second and third level. The patients included were ≤18 years old hospitalized in the children wards; those admitted at the emergency room, neonatal intermediate and intensive therapy units were not included. Medical prescriptions were reviewed taking into consideration anthropometric characteristics, diagnosis and number of drugs prescribed to identify potential drug-drug interactions using Micromedex 2.0 database. Results: 88 patients were included, an average of 4.6 ± 2.8 of drugs were prescribed per patient. 37 subjects (42%) presented some degree of potential drug-drug interactions of which 25.5% were major and 27.7% moderate according to the software. Identified risk factors were: age ≥ 4 years (OR 1.917; 95% CI 1.081-3.399), BSA ≥ 0.8m2(OR 1.825; 95% CI 1.021-3.263), height ≥ 1 m (OR 2.556;95% CI 1.322 - 4.941), and number of prescribed medications ≥ 4 (OR 2.106;95% CI 1.248 - 3.556). Conclusion: Some of the interactions found were for the benefit of the patient, but others were considered undesirable because they altered the pharmacokinetics of some of the medications administered. Detecting in time the harmful interactions for a patient may favor the patient's safety. Competing Interests: Declaration of Competing Interest The authors declare that they have no competing interest. (Copyright © 2019. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu